Impaired TLR5 Functionality Is Associated with Survival in Melioidosis


*J Immunol* published online 27 February 2013
http://www.jimmunol.org/content/early/2013/02/24/jimmunol.1202974
Impaired TLR5 Functionality Is Associated with Survival in Melioidosis

T. Eoin West,*,† Narisara Chantratita,‡,§ Wirongrong Chierakul,‡,¶ Direk Limmathurotsakul,‡,∥ Vanaporn Wuthiekanun,‡ Nicole D. Myers,† Mary J. Emond,‡ Mark M. Wurfel,† Thomas R. Hawn,** Sharon J. Peacock,‡,†† and Shawn J. Skerrett‡

Melioidosis is infection caused by the flagellated saprophyte Burkholderia pseudomallei. TLR5 is a pathogen recognition receptor activated by bacterial flagellin. We studied a genetic variant that encodes a defective TLR5 protein, TLR5<sup>1174C>T, to elucidate the role of TLR5 in melioidosis. We measured NF-κB activation induced by B. pseudomallei in human embryonic kidney–293 cells transfected with TLR5<sup>1174C</sup> but not TLR5<sup>1174T</sup>-dependent activation of NF-κB. We tested the association of TLR5<sup>1174C>T</sup> with outcome in 600 Thai subjects with melioidosis. In a dominant model, TLR5<sup>1174C>T</sup> was associated with protection against in-hospital death (adjusted odds ratio: 0.20; 95% confidence interval: 0.08–0.50; p = 0.001) and organ failure (adjusted odds ratio: 0.37; 95% confidence interval: 0.19–0.71; p = 0.003). We analyzed blood cytokine production induced by flagellin or heat-killed B. pseudomallei by TLR5<sup>1174C>T</sup> genotype in healthy subjects. Flagellin induced lower monocyte-normalized levels of IL-6, IL-8, TNF-α, IL-10, MCP-1, IL-1ra, G-CSF, and IL-1β in carriers of TLR5<sup>1174C</sup> B. pseudomallei induced lower monocyte-normalized levels of IL-10 in carriers of TLR5<sup>1174T</sup>. We conclude that the hypofunctional genetic variant TLR5<sup>1174C>T</sup> is associated with reduced organ failure and improved survival in melioidosis. This conclusion suggests a deleterious immunoregulatory effect of TLR5 that may be mediated by IL-10 and identifies this receptor as a potential therapeutic target in melioidosis. The Journal of Immunology, 2013, 190: 000–000.

Melioidosis is infection caused by the Gram-negative, flagellated soil saprophyte and putative bioweapon Burkholderia pseudomallei, which is endemic in parts of southeast Asia and northern Australia (1). Sepsis, the clinical manifestation of the host inflammatory response to infection, is a common clinical presentation of disease, and the lung is the organ most commonly involved (1). In northeast Thailand, where B. pseudomallei is the most common bloodstream isolate, the overall melioidosis mortality rate exceeds 40% and pneumonia confers >two-fold increase in risk of death (2).

Outcome from bacterial infection is dependent on host innate immunity. We and others have previously shown that TLR2 and TLR4—transmembrane pathogen recognition receptors—regulate host responses in B. pseudomallei infection in vitro and in vivo (3, 4). TLR5, a sensor of bacterial flagellin, regulates host defense to a number of lung infections caused by flagellated bacteria (5–9). The importance of TLR5 in regulating the host response to human melioidosis has not been determined.

Host genetic composition determines susceptibility to infection (10, 11). Analysis of genetic variation offers the opportunity to assess the role of specific elements of host innate immunity in human disease (11, 12). A single nucleotide polymorphism in TLR5, TLR5<sup>1174C>T</sup>, is present with a minor allele frequency (MAF) of 5–8% in white and Asian populations. TLR5<sup>1174T</sup> prematurely truncates the TLR5 receptor in the extracellular domain, eliminating the transmembrane and cytoplasmic signaling domains of the receptor (6). This action results in reduced flagellin-dependent activation of innate immunity and host inflammatory responses, possibly in a dominant fashion (6). TLR5<sup>1174T</sup> has been associated with susceptibility to Legionnaire’s disease in a cohort of Dutch subjects exposed to contaminated water (6) but has not been associated with outcome from infection. We proposed testing the role of TLR5 in melioidosis by analyzing the association of TLR5<sup>1174C>T</sup> with outcome in Thais with melioidosis.
Materials and Methods

Bacteria

*B. pseudomallei* BP-1, *B. pseudomallei* 1026b, or *B. pseudomallei* K96243 organisms were grown in Luria–Bertani broth for 6 h (log phase) or 19 h (stationary phase) and heat killed as previously described (3).

**Human subjects**

The melioidosis case–control study cohort has been previously described (13). Clinical data and blood were obtained prospectively from patients with culture-proven melioidosis admitted to Sappasithiprasong Hospital, Ubon Ratchathani, Thailand, from 1999 to 2005. Consent for enrollment into clinical studies of melioidosis was obtained from subjects or their representatives at the time of recruitment.

For studies using whole blood, fasting blood samples were obtained from healthy white participants in a Harborview Medical Center inflammatory response research study. Enrollment criteria and blood processing have been previously described (14). Thai subjects donating blood at the blood donation center at Sappasithiprasong Hospital in 2010 were recruited for participation in a similar study. Subjects were included if they were between the ages of 18 and 60 and did not report any history of immunodeficiency or inflammatory conditions, chronic diseases, pregnancy in the past 6 mo, anti-inflammatory medication use in the past week, antibiotic use in the past 6 mo, heavy exercise or alcohol consumption in the past 24 h, or smoking in the past month. Those who met enrollment criteria gave written informed consent to participate and provided a postdonation blood sample.

These studies were approved by the University of Washington Human Subjects Division Institutional Review Board; the Ethical Review Committee for Research in Human Subjects, Ministry of Public Health, Thailand; the Ethical Review Committee for Research in Human Subjects, Sappasithiprasong Hospital, Ubon Ratchathani, Thailand; and the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

**Assays**

NF-κB activation was determined with a luciferase reporter assay in Chinese hamster ovary (CHO) cells stably expressing huTLR5 and in human embryonic kidney–293 cells (HEK-293) transiently transfected with huTLR5<sub>1174T</sub> or huTLR5<sub>1174F</sub>, as previously described (6, 15, 16).

For immunoaassays, 380 μl fresh whole blood in citrate mixed 1:1 with RPMI 1640 media was added to preprepared plates containing 20 μl stimulants. For the Harborview Medical Center study, the stimulant was log phase heat-killed *B. pseudomallei* 1026b 2.5 × 10<sup>6</sup> CFU/ml. For the Sappasithiprasong Hospital study, the stimulants were E. coli 0111:B4 LPS 10 ng/ml, *S. typhimurium* flagellin 500 ng/ml, log phase heat-killed *B. pseudomallei* 1026b 2.5 × 10<sup>6</sup> CFU/ml, or heat-killed *B. pseudomallei* K96243 2.5 × 10<sup>6</sup> CFU/ml. Plates were incubated at 37˚C on a shaking incubator under 5% CO<sub>2</sub> for 6 h before being spun down and the plasma was removed and frozen. For the Harborview Medical Center study, plasma IFN-γ, IL-10, IL-12p70, IL-1β, IL-6, IL-8, and TNF-α were subsequently assayed in duplicate, using an electrochemiluminescence imager (Mesoscale Discovery, Gaithersburg, MD). For the Sappasithiprasong Hospital study, IL-6, IL-8, TNF-α, IL-10, MCP-1, IL-1ra, G-CSF, and IL-1β were later assayed in duplicate on a multiplex bead system (Luminex, Austin, TX) using reagents from R&D Systems (Minneapolis, MN) or by ELISA (IL-1β for *B. pseudomallei* only) (14, 15). For each subject, a complete blood count with differential was performed in the clinical laboratory at the time of phlebotomy.

**Genetic methods**

DNA was extracted from whole blood using Nucleon BACC3 (GE Healthcare, Buckinghamshire, U.K.) or QIAamp DNA Blood Midi (Qiagen, Hilden, Germany) kits (13). Genotyping was performed using an allele-specific primer extension method (Sequenom, San Diego, CA) with reads by a MALDI-TOF mass spectrometer (13) or was performed using ABI TaqMan assays on an ABI Prism 7900 (Applied Biosystems, Carlsbad, CA).

**Statistics**

Continuous clinical data are reported as mean values. The association between genotype and outcome was evaluated using the Fisher exact test or by logistic regression. Survival analyses were performed with the log-rank test. For tests of population stratification, allele counts between cases and controls were compared with the χ<sup>2</sup> test. Continuous in vitro data expected to follow a normal distribution are reported as mean ± SD. Comparisons between two groups were made using the t test, and comparisons between three or more groups were made using ANOVA and the Bonferroni posttest. Data not normally distributed are reported as median ± interquartile range. Plasma cytokine levels were analyzed in raw form or following normalization to monocyte counts. Given their mostly nonnormal distributions, cytokine values were log<sub>10</sub>-transformed before analysis by linear regression, adjusting for sex in the Thai cohort (14). Statistics were performed with Stata 11.1 (College Station, TX), incorporating the function genhw. A two-sided p ≤ 0.05 was considered significant.

**Results**

**TLR5 mediates activation of NF-κB by *B. pseudomallei***

We first tested whether *B. pseudomallei* activates NF-κB, a transcription factor in the TLR pathway, in a TLR5-dependent manner. As wild-type CHO cells do not respond to flagellin (5), we stimulated CHO cells stably transfected with huTLR5 and an NF-κB luciferase reporter with stationary and log phase killed *B. pseudomallei* BP-1 (Fig. 1) (16). We examined bacteria from different growth phases because of lost or reduced expression of bacterial flagellin by *B. pseudomallei* in the stationary phase (S. Peacock, unpublished observations). Although stimulation with only the higher concentrations of stationary phase bacteria resulted in NF-κB activation, we detected robust NF-κB activation upon stimulation with lower concentrations of log phase bacteria. These findings indicated TLR5-mediated innate immune activation by *B. pseudomallei*.

**TLR5<sub>1174F</sub> is associated with protection against death in human melioidosis***

To explore the importance of TLR5 signaling in human melioidosis, we selected a common hypofunctional human polymor-
phism, TLR5<sub>1174C>T</sub> (rs5744168), for study. In a case–control study, we analyzed the association of TLR5<sub>1174C>T</sub> with outcome in a cohort of Thai subjects with culture-proven melioidosis admitted to Sappasithiprasong Hospital. Of 614 subjects with blood available for genotyping who passed quality control checks, survival at hospital discharge was known for 600. Mortality was 23.8%. The characteristics of the melioidosis subjects are listed in Table I. We successfully genotyped TLR5<sub>1174C>T</sub> in 592 individuals (98.7% call rate); 514 (86.8%) were genotype C/C, 76 (12.8%) C/T, and 2 (0.3%) T/T (MAF 6.8%). After confirming Hardy–Weinberg equilibrium in the survivors (p = 0.8), we tested the association of the variant with in-hospital death. We found that 15.9% of survivors were heterozygotes or minor homozygotes, compared with 4.3% of nonsurvivors (contingency table p = 0.0004) (Table II). In a dominant genetic model (grouping carriers of the rare allele—TLR5<sub>1174CT</sub> and TLR5<sub>1174TT</sub>—together), we observed a very strong association of the TLR5<sub>1174C>T</sub> variant with protection against death [odds ratio (OR): 0.24; 95% confidence interval (CI): 0.10–0.56; p = 0.001].

We next performed an adjusted association of the TLR5<sub>1174C>T</sub> variant with in-hospital death. To identify possible confounders to include in the model, we tested whether TLR5<sub>1174C>T</sub> was associated with any pre-existing condition (diabetes, chronic liver disease, renal insufficiency, and steroid use). We found no association of the variant with any of these factors. However, we considered in the model factors that were independently associated with death: age, diabetes, renal insufficiency, pneumonia, bacteremia, and urinary tract infection. The appropriateness of the model of the association of TLR5<sub>1174C>T</sub> with death was tested by comparing allele frequencies in nonsurvivors with those in survivors ( contingency table p = 0.58 for a dominant model).

TLR4<sub>896A>G</sub> is significantly associated with protection against death [OR of death: 4.97; 95% CI: 0.82–30.0; p = 0.08 for a dominant model]. TIRAP<sub>558C>T</sub> has a MAF ~5% (13) but in melioidosis patients, TIRAP<sub>558T</sub> was not significantly associated with death (OR of death: 0.83; 95% CI: 0.44–1.58; p = 0.58 for a dominant model). In the model of the association of TLR5<sub>1174T</sub> with death, neither TLR4<sub>896G</sub> nor TIRAP<sub>558T</sub> was significant (p = 0.06 or p = 0.49, respectively) or changed the main effect of TLR5<sub>1174T</sub>. In the final model of the association of TLR5<sub>1174T</sub> with death, adjusting for age, diabetes, renal insufficiency, pneumonia, and bacteremia, the protective effect remained very strong (OR: 0.20; 95% CI: 0.08–0.50; p = 0.001).

We plotted Kaplan–Meier in-hospital survival curves by TLR5<sub>1174C>T</sub> genotype for all melioidosis cases (Fig. 2). A significant difference was noted in the risk of death between 0 and 30 d for individuals having TLR5<sub>1174CC</sub> genotypes compared with those having TLR5<sub>1174CT</sub> (or TLR5<sub>1174TT</sub>) genotypes by the log-rank test (p = 0.001).

To test whether systemic ancestry differences (population stratification) between cases and controls contributed substantially to our findings, we examined the frequency of 25 unrelated single nucleotide polymorphisms from across the genome (13, 25). We compared the allele frequency of these variants in HapMap European ancestry and Han Chinese Beijing populations and selected the 17 variants with a χ<sup>2</sup> > 1.5 (mean χ<sup>2</sup> = 22.3). These variants were considered maximally variable between the two populations and might therefore serve as markers of population variation in our cohort. We genotyped these variants in the subset of 434 melioidosis subjects whose DNA was assayed on the Sequenom platform and compared allele frequencies in nonsurvivors with those in survivors (Supplemental Table I). The mean χ<sup>2</sup> of all 17 variants was 1.14, suggesting little population stratification (26).

**Table I. Characteristics of subjects with melioidosis**

<table>
<thead>
<tr>
<th>Baseline characteristic</th>
<th>All&lt;sup&gt;a&lt;/sup&gt; (n = 600)</th>
<th>Nonsurvivors (n = 143)</th>
<th>Survivors (n = 457)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
<td>48.6</td>
<td>51.7</td>
<td>47.7</td>
</tr>
<tr>
<td>Female sex</td>
<td>46</td>
<td>43</td>
<td>47</td>
</tr>
<tr>
<td>Pre-existing condition&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>52</td>
<td>44</td>
<td>55</td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td>7</td>
<td>13</td>
<td>5</td>
</tr>
<tr>
<td>Steroid use</td>
<td>6</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Clinical presentation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacteremia</td>
<td>50</td>
<td>73</td>
<td>43</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>38</td>
<td>57</td>
<td>33</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>12</td>
<td>19</td>
<td>10</td>
</tr>
<tr>
<td>Clinical course</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shock</td>
<td>26</td>
<td>61</td>
<td>15</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>18</td>
<td>68</td>
<td>2</td>
</tr>
<tr>
<td>Organ failure&lt;sup&gt;c&lt;/sup&gt;</td>
<td>32</td>
<td>81</td>
<td>17</td>
</tr>
</tbody>
</table>

Numbers are a percentage except for mean age.

<sup>a</sup>Missing data for 4 subjects (bacteremia), 4 subjects (pneumonia), 4 subjects (urinary tract infection), 39 subjects (shock), 29 subjects (respiratory failure), 40 subjects (organ failure).

<sup>b</sup>Unknown pre-existing conditions are considered negative.

<sup>c</sup>Organ failure is defined as presence of shock or respiratory failure.
genotype $\text{TLR5}_{1174CT}$ or $\text{TLR5}_{1174TT}$, compared with 16.3% of subjects who did not develop organ failure (Table II). In an unadjusted dominant model of the association of the $\text{TLR5}_{1174CT}$ or $\text{TLR5}_{1174TT}$ with organ failure, the OR was 0.44 (95% CI: 0.24–0.81; $p = 0.009$). Age, diabetes, pneumonia, bacteremia, and urinary tract infection were independently associated with organ failure, and so were considered in the adjusted model. In the final model incorporating diabetes, pneumonia, and bacteremia, the OR for the association of $\text{TLR5}_{1174CT}$ or $\text{TLR5}_{1174TT}$ with organ failure was 0.37 (95% CI: 0.19–0.71; $p = 0.003$).

$\text{TLR5}_{1174T}$ does not mediate activation of $\text{NF-\kappa B}$ by $B. pseudomallei$

We next asessed how $\text{TLR5}_{1174T}$ modulates innate immune activation by $B. pseudomallei$ in isolation in vitro. As HEK-293 cells do not endogenously express TLRs (27), we transiently transfected HEK-293 cells with either $\text{TLR5}_{1174C}$ or $\text{TLR5}_{1174T}$ and an NF-\kappa B luciferase reporter before stimulating the cells with heat-killed log phase $B. pseudomallei$ (Fig. 3). In contrast to $\text{TLR5}_{1174C}$, $\text{TLR5}_{1174T}$ was unable to mediate $B. pseudomallei$-induced NF-\kappa B activation.

B. pseudomallei induces reduced blood cytokine responses ex vivo in carriers of $\text{TLR5}_{1174T}$

Together, these findings suggested that carriers of $\text{TLR5}_{1174T}$ may generate impaired inflammatory responses during melioidosis infection that result in reduced organ failure and lower mortality. To establish whether $\text{TLR5}_{1174CT}$ or $\text{TLR5}_{1174TT}$ is associated with altered cytokine production in response to $B. pseudomallei$ in humans, we obtained blood from 11 healthy white subjects of known $\text{TLR5}_{1174CT}$ or $\text{TLR5}_{1174TT}$ genotype. We stimulated fresh whole blood ex vivo with heat-killed 1026b. We measured IFN-\gamma, IL-10, IL-12p70, IL-1\beta, IL-6, IL-8, and TNF-\alpha in plasma. We found no $\text{TLR5}_{1174CT}$ or $\text{TLR5}_{1174TT}$ genotype-dependent differences in raw cytokine production induced by $B. pseudomallei$. We have found that cytokine levels induced by $B. pseudomallei$ are dependent on leukocyte count (N. Chantratita, submitted for publication). The $\text{TLR5}_{1174CT}$ or $\text{TLR5}_{1174TT}$ in innate immune responses to $B. pseudomallei$.

To confirm this effect in a larger cohort and to determine whether this effect was also apparent in a Thai population susceptible to melioidosis, we obtained blood from 300 healthy blood donors at Sappasithiprasong Hospital. We stimulated fresh whole blood with LPS, flagellin, or heat-killed 1026b. We quantified IL-6, IL-8, TNF-\alpha, IL-10, MCP-1, IL-1ra, G-CSF, and IL-1\beta levels in plasma. We genotyped the subjects at $\text{TLR5}_{1174T}$ and found that 269 (90%) subjects were major homozygotes, 31 (10%) were heterozygotes, and 0 (0%) were minor homozygotes (MAF 5.2%). In this cohort, we did not observe any $\text{TLR5}_{1174CT}$ or $\text{TLR5}_{1174TT}$-dependent differences in total leukocyte count ($p = 0.22$) or monocyte count ($p = 0.54$). Flagellin stimulation

**FIGURE 2.** Survival from melioidosis is enhanced for carriers of $\text{TLR5}_{1174T}$. Kaplan–Meier in-hospital survival curves are plotted for melioidosis subjects, grouped by genotype. Curves are significantly different by the log rank test ($p = 0.001$).

**FIGURE 3.** NF-\kappa B activation induced by $B. pseudomallei$ is abrogated by $\text{TLR5}_{1174T}$. HEK-293 cells transiently transfected with human $\text{TLR5}_{1174C}$ or $\text{TLR5}_{1174T}$, NF-\kappa B-dependent firefly ELAM luciferase, and control thymidine kinase–driven Renilla luciferase were stimulated with media alone, IL-1\beta 20 ng/ml, S. typhimurium flagellin 100 ng/ml, or log phase killed B. pseudomallei 1026b at various concentrations in colony-forming units per milliliter. NF-\kappa B activation was determined by the ratio of ELAM to Renilla light emission after 24 h. Data plotted are means ± SDs of triplicate or quadruplicate conditions that represent one of two similar experiments performed independently. **$p \leq 0.001$ by ANOVA with the Bonferroni posttest for comparisons between similarly stimulated cells transfected with empty vector $\text{TLR5}_{1174C}$ or $\text{TLR5}_{1174T}$.
of blood from subjects with the TLR5<sup>1174CT</sup> genotype, compared with TLR5<sup>1174CC</sup> subjects, induced significantly lower levels of all raw cytokine responses except IL-1ra (e.g., median TNF-α concentrations were 260.6 pg/ml compared with 632.7 pg/ml, \( p < 0.001 \)) and significantly lower levels of all monocyte-normalized cytokine responses (Fig. 5). Stimulation with LPS, a TLR4 agonist, induced no TLR5<sup>1174C</sup>.T-dependent difference in raw or normalized cytokine levels. Stimulation with both strains of B. pseudomallei induced no significant differences in raw cytokine responses, but both strains induced significantly less monocyte-normalized IL-10, and a trend toward lower monocyte-normalized IL-8 levels was observed (\( p = 0.057 \) and \( p = 0.084 \)) in TLR5<sup>1174CT</sup> subjects. K96243 also induced significantly less G-CSF in TLR5<sup>1174CT</sup> subjects after normalization for monocyte count.

**Discussion**

The results of this study provide compelling evidence of the importance of TLR5 as a regulator of the host response in melioidosis. In the largest investigation to date of genetic variation as a determinant of outcome from melioidosis, we show that B. pseudomallei induces a TLR5-dependent innate immune response and that a TLR5 genetic variant that encodes a defective TLR5 protein is associated with marked protection against death or organ failure in Thais. We further demonstrate a functional effect of this variant in the blood cytokine response to flagellin and to killed B. pseudomallei.

Although TLR5<sup>1174C</sup>T is associated with susceptibility to Legionnaires’ disease (Legionella pneumophila pneumonia) and recurrent urinary tract infections (6, 28), our study is the first, to our knowledge, to identify an association of the variant with outcome from infection. TLR5<sup>1174T</sup> has previously been shown to blunt flagellin-dependent IL-6 and IL-8 release in whole blood (6, 14). In addition, we show that levels of IL-10, TNF-α, MCP-1, G-CSF, IL-1ra, and IL-1β induced by flagellin are also reduced in carriers of the variant. It is therefore tempting to postulate that the hypofunctional TLR5 variant broadly impairs the inflammatory response to flagellated infection, resulting in reduced sepsis-induced organ failure and death. This idea is consistent with other studies showing that carriage of the variant is protective in inflammatory conditions, including systemic lupus erythematosus, cystic fibrosis (the variant is associated with a higher body mass index), and Crohn’s disease (29–31). However, IL-10 is the sole cytokine that is consistently reduced in carriers of TLR5<sup>1174T</sup> from Thai carriers of TLR5<sup>1174T</sup>. Whole blood was stimulated with media, E. coli 0111:B4 LPS 10 ng/ml, S. typhimurium flagellin 500 ng/ml, or heat-killed B. pseudomallei K96243 2.5 × 10<sup>6</sup> CFU/ml (K9) for 6 h. Inflammatory mediators were measured in plasma by multiplex bead assay or ELISA (IL-1β for B. pseudomallei only), normalized to monocyte count, and log<sub>10</sub>-transformed for statistical analysis by linear regression. Boxes show the median and interquartile range; whiskers show upper and lower adjacent values; outside values are not shown for clarity. *\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \).
two different populations upon stimulation of blood with whole 
*B. pseudomallei*, suggesting an effect of the variant that is restricted to 
IL-10 production when innate immunity is simultaneously ac-
tivated by multiple ligands. IL-10 is an anti-inflammatory cytokine 
clearly implicated in sepsis, although its role in modulating the 
host response during this complex and dynamic process remains 
poorly understood (32, 33). In a clinical trial of antibiotic therapy 
in melioidosis, baseline IL-10 levels were increased in non-
 survivors of melioidosis, compared with those in survivors, and 
the IL-10 level was an independent predictor of mortality (34). A 
recent study of inhalation melioidosis in African green monkeys 
found that increased IL-10 levels correlated with reduced survival 
time on day four following infection (35). These data are con-
dictory with our findings. Conceivably, impaired IL-10 release in 
carriers of *TLR5* may, in fact, enhance inflammation and 
control of the invading pathogen in the early stages of infection, 
resulting in improved organ function and survival. Further inves-
tigation is required to elucidate the TLR5-driven and IL-10-de-
pendent mechanisms at play during melioidosis.

We have previously examined the association of TLR genetic 
variants with susceptibility to melioidosis (13) but did not detect 
any relationship between TLR5*1174C>T* and disease. These con-
trasting observations underscore the very different roles the innate 
immune system plays in modulating host susceptibility to infec-
tion versus governing outcome once infection is established. It is 
often difficult to ascertain the specific route of infection—percu-
taneous versus inhalaed—in clinical cases of melioidosis. However, 
the differential associations of TLR5*1174C>T* with melioidosis 
compared with *Legionella* pneumonia further highlight the im-
portance of additional immune modulators in governing clinical 
responses to airborne infection caused by flagellated organisms. 
The protective effect of TLR5*1174T* on outcome from melioidosis 
and in susceptibility to various inflammatory conditions may ex-
plain the relatively high frequency of the hypofunctional allele in 
a variety of populations.

Our genetic association study has several limitations. Despite 
our best efforts to select cases and controls appropriately and test 
for population stratification, unmeasured population stratification 
might bias our analyses. A second limitation is that the observed 
mortality in this cohort was lower than in previous descriptions of 
outcome from melioidosis at this hospital (36). This observation is 
important due to the bias in this study against subjects who died 
before admission and did not have blood collected for 
genotyping by the study team. In addition, our genetic associ-
ation will require replication in a second, independent population.

However, as Sappasutiphronang Hospital is one of the few sites with 
sufficient infrastructure to perform such a genetic study in melioid-
osis, we designed as large a clinical study as possible at this single 
site and performed functional experiments in a similar population.

In summary, a common TLR5 genetic variant that prematurely 
truncates TLR5 and abrogates TLR5-dependent signaling is 
strongly associated with improved outcome in human melioidosis. 
Ex vivo blood stimulation studies indicate that IL-10 is implicated in 
this process. To our knowledge, this is the first study to suggest 
an essential role for TLR5 in regulation of the host immune re-
 sponse in melioidosis. Our findings prompt further evaluation of 
this receptor as a potential target for therapeutic intervention in 
this severe infection.

Acknowledgments

We thank the staff and patients at Sappasutiphronang Hospital for support; 
Premjit Amornchai, Aunchalee Thanwisai, and Malinee Oyuchua for DNA 
 extraction; and Malinka Jansson and Saruporn Tandhavannat for technical assistance.

Disclosures

The authors have no financial conflicts of interest.

References


Our genetic association study has several limitations. Despite our best efforts to select cases and controls appropriately and test for population stratification, unmeasured population stratification may bias our analyses. A second limitation is that the observed mortality in this cohort was lower than in previous descriptions of outcome from melioidosis at this hospital (36). This observation is most likely due to a bias in this study against subjects who died extremely rapidly after admission and did not have blood collected for 
genotyping by the study team. In addition, our genetic associ-
ation will require replication in a second, independent population.

However, as Sappasutiphronang Hospital is one of the few sites with 
sufficient infrastructure to perform such a genetic study in melioid-
osis, we designed as large a clinical study as possible at this single 
site and performed functional experiments in a similar population.

In summary, a common TLR5 genetic variant that prematurely 
truncates TLR5 and abrogates TLR5-dependent signaling is 
strongly associated with improved outcome in human melioidosis. 
Ex vivo blood stimulation studies indicate that IL-10 is implicated in 
this process. To our knowledge, this is the first study to suggest 
an essential role for TLR5 in regulation of the host immune re-
sponse in melioidosis. Our findings prompt further evaluation of 
this receptor as a potential target for therapeutic intervention in 
this severe infection.

Acknowledgments

We thank the staff and patients at Sappasutiphronang Hospital for support; 
Premjit Amornchai, Aunchalee Thanwisai, and Malinee Oyuchua for DNA 
 extraction; and Malinka Jansson and Saruporn Tandhavannat for technical assistance.


Supplemental Table I: Frequency distribution of population stratification SNPs in melioidosis subjects

<table>
<thead>
<tr>
<th>SNP</th>
<th>Chromosome</th>
<th>Status</th>
<th>Allele 1 Count</th>
<th>Allele 2 Count</th>
<th>$\chi^2$</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs1028184</td>
<td>2</td>
<td>Survivors</td>
<td>300</td>
<td>364</td>
<td>0.08</td>
<td>0.78</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-survivors</td>
<td>89</td>
<td>113</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2056773</td>
<td>3</td>
<td>Survivors</td>
<td>60</td>
<td>606</td>
<td>1.01</td>
<td>0.31</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-survivors</td>
<td>23</td>
<td>179</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2048022</td>
<td>4</td>
<td>Survivors</td>
<td>382</td>
<td>284</td>
<td>3.14</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-survivors</td>
<td>130</td>
<td>72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1479067</td>
<td>5</td>
<td>Survivors</td>
<td>111</td>
<td>551</td>
<td>3.42</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-survivors</td>
<td>23</td>
<td>179</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs327747</td>
<td>7</td>
<td>Survivors</td>
<td>549</td>
<td>111</td>
<td>1.43</td>
<td>0.23</td>
</tr>
<tr>
<td>rs</td>
<td>Length</td>
<td>Survivors</td>
<td>Non-survivors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>-----------</td>
<td>---------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1380229</td>
<td>8</td>
<td>282</td>
<td>159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs650389</td>
<td>10</td>
<td>268</td>
<td>94</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs695982</td>
<td>12</td>
<td>554</td>
<td>90</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs870384</td>
<td>12</td>
<td>547</td>
<td>162</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs914904</td>
<td>13</td>
<td>413</td>
<td>134</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNP</td>
<td>MAF</td>
<td>Survivors</td>
<td></td>
<td>Non-survivors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-----</td>
<td>-----------</td>
<td>---</td>
<td>----------------</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>rs975423</td>
<td>0.13</td>
<td>61</td>
<td>603</td>
<td>0.27</td>
<td>0.61</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>16</td>
<td>184</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs715774</td>
<td>0.15</td>
<td>641</td>
<td>25</td>
<td>0.57</td>
<td>0.45</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>192</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1566838</td>
<td>0.16</td>
<td>407</td>
<td>259</td>
<td>0.03</td>
<td>0.86</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>122</td>
<td>80</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1582598</td>
<td>0.16</td>
<td>210</td>
<td>456</td>
<td>0.69</td>
<td>0.41</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>70</td>
<td>132</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs807131</td>
<td>0.17</td>
<td>521</td>
<td>145</td>
<td>0.09</td>
<td>0.76</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>156</td>
<td>46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs11672183</td>
<td>0.19</td>
<td>518</td>
<td>144</td>
<td>3.13</td>
<td>0.08</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs739259</td>
<td>22</td>
<td>Survivors</td>
<td>361</td>
<td>289</td>
<td>1.53</td>
<td>0.22</td>
</tr>
<tr>
<td>----------</td>
<td>----</td>
<td>-----------</td>
<td>-----</td>
<td>-----</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Non-</td>
<td></td>
<td>survivors</td>
<td>168</td>
<td>32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-</td>
<td></td>
<td>survivors</td>
<td>121</td>
<td>79</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>